Smaller companies prove outsized IP impact

The 2026 Top 100 confirms that innovation momentum is not limited to global conglomerates.  

Smaller, specialist players such as  Acuitas Therapeutics, Strong Force IP, Ofinno, and Magic Leap demonstrate how focused capabilities and high-value IP can create disproportionate strategic relevance.  

This dynamic reinforces that patent portfolio quality, not organizational size, determines innovation impact.  This is a test.